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Abstract
Severe acute respiratory syndrome (SARS), caused by the coronavirus SARS-CoV, is an acute infectious disease with
significant mortality. A typical clinical feature associated with SARS is pulmonary fibrosis and associated lung failure. In the
aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism
of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host
cell at the onset of infection. The rapidly changing viral genome adds another variable to this equation. We have focused on
a novel concept of microRNA (miRNA)–mediated host–virus interactions in bronchoalveolar stem cells (BASCs) at the onset
of infection by correlating the ‘‘BASC–microRNome’’ with their targets within BASCs and viral genome. This work
encompasses miRNA array data analysis, target prediction, and miRNA–mRNA enrichment analysis and develops a complex
interaction map among disease-related factors, miRNAs, and BASCs in SARS pathway, which will provide some clues for
diagnostic markers to view an overall interplay leading to disease progression. Our observation reveals the BASCs (Sca-1+
CD34+ CD45- Pecam-), a subset of Oct-4+ ACE2+ epithelial colony cells at the broncho-alveolar duct junction, to be the
prime target cells of SARS-CoV infection. Upregulated BASC miRNAs-17*, -574-5p, and -214 are co-opted by SARS-CoV to
suppress its own replication and evade immune elimination until successful transmission takes place. Viral Nucleocapsid and
Spike protein targets seem to co-opt downregulated miR-223 and miR-98 respectively within BASCs to control the various
stages of BASC differentiation, activation of inflammatory chemokines, and downregulation of ACE2. All these effectively
accounts for a successful viral transmission and replication within BASCs causing continued deterioration of lung tissues and
apparent loss of capacity for lung repair. Overall, this investigation reveals another mode of exploitation of cellular miRNA
machinery by virus to their own advantage.
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Introduction
Severe Acute Respiratory Syndrome (SARS) is a new fulminant
atypical pneumonia which emerged as a regional and global threat
in 2002–2003 with a high mortality rate resulting from acute lung
failure [1]. The disease causing agent has been identified as a novel
coronavirus termed as SARS-associated coronavirus (SARS-CoV)
[2,3]. The SARS-CoV is an enveloped virus containing a single
stranded, positive-sense RNA genome which encodes 14 putative
open reading frames encoding 28 potential proteins [4,5]. These
include four structural proteins, spike (S) glycoprotein, matrix (M)
protein, small envelope (E) protein, and nucleocapsid (N) protein
[4]. These proteins have various roles in aiding the virus to enter
the host and spread infection. While the incidence of new cases of
SARS waned in 2003–2004, many aspects of SARS disease
pathogenesis and host-pathogen interactions remain unsolved.
Limited pathologic studies reveal that the major site of SARS-CoV
infection and morbidity is the respiratory tract. The target organ
of SARS is mainly lungs [6]. Among the various animal models
that have been used to study the pathogenesis of SARS-CoV
infection, the monkey model mimics the clinical course of SARS to
a certain degree [7]. The cellular tropism of SARS-CoV in mouse
lung has also been investigated by Ling et al., 2006 [8]. But still
today, very little is known regarding the mode of SARS-CoV
interaction with host cells at the onset of infection in the lungs at a
molecular level, and also the cell types in which the primary viral
infection and replication occurs.
The lung is an extremely complex, conditionally renewing
organ which contains anatomically and functionally distinct
epithelial stem cell populations which reside in distinct anatomical
locations. The basal cells [9], Clara cells [10] and type-II pneumo-
cytes [11] are the candidate stem/progenitor cells which can repair
the injured lungs and contribute to local needs in times of tissue
damage. Recently, Kim et al. have isolated a regional pulmonary
stem cell population termed as bronchoalveolar stem cells (BASCs)
residing at the bronchoalveolar duct junction of adult lungs [12].
These have been identified and characterized as CD34
+ Sca-1
+
CD45
- PE-CAM
2 cells expressing both cytoplasmic Clara cell
secretion protein (CCSP) and prosurfactant protein-C proteins,
which are markers for Clara cells and type-II pneumocytes respec-
tively [12]. We have searched for the evidence to establish BASC as
the prime target cells of SARS infection initiation and replication.
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an essential tool to understand the regulatory pathways at
molecular level that underlie infection biology [13,14]. They not
only participate in executive decisions but also perform much of
the grunt work to micromanage protein output. Inspite of being
such potential regulatory elements, miRNAs have so far missed
attention in the pathogenesis of SARS-CoV infection.
MiRNAs are small (19–25 nucleotides) endogenous noncoding
RNAs that have been shown to influence the abundance and
translational efficiency of cognate mRNAs [15,16]. Viruses, which
typically employ many components of the host gene expression
machinery, also encode miRNAs. On the contrary, miRNA-
biogenesis pathway poses some serious problem for RNA viruses
and a group of DNA viruses (poxviruses) to encode miRNAs [14].
SARS-CoV being an RNA virus is assumed not to encode its own
miRNAs. But in due course of evolution, the virus might have
developed certain highly sophisticated molecular mechanisms to
exploit the cellular biosynthetic machinery of host cells and elude
the cellular defense mechanisms. It is most likely that in certain
situations SARS-CoV uses the cellular miRNA transcripts in order
to foster their own agenda.
Given the proposed involvement of BASCs in SARS disease [8],
elucidation of the miRNA-mediated regulatory mechanisms
responsible for making BASCs the prime targets of SARS
infection might provide new avenues to explore the underlying
mechanisms of SARS infection.
Onset of SARS infection
The entry of SARS-CoV into cells is mediated through
interaction between spike (S) glycoprotein of the virus and
angiotensin-converting enzyme 2 (ACE2), the primary receptor
of SARS-CoV on the host cell [17]. ACE2 is a homolog of
angiotensin-converting enzyme (ACE), which plays an important
role in the renin–angiotensin system for blood pressure homeo-
stasis. Recent studies of Li et al. [18] have shown a protective effect
of ACE2 against experimental lung fibrosis through its ability to
degrade local tissue angiotensin II (ANG II) in response to
bleomycin. Furthermore, in the pathogenesis of lung fibrosis, they
have proposed the involvement of the down regulation of ACE2 as
an integral component of the sequence of events leading to lung
collagen deposition. The molecular mechanisms responsible for
the loss of ACE2 in lung fibrosis are currently under investigation.
A typical clinical feature associated with SARS is also pulmonary
fibrosis and associated lung failure whose underlying mechanism
still remains elusive [19]. Investigations leading to the underlying
molecular mechanisms responsible for the loss of ACE2 in
pulmonary fibrosis might provide a clue to the reason behind
fibrosis associated lung injury in SARS.
Several reports suggest that there is a close interaction between
SARS-CoV and respiratory epithelia which play an important role
in the genesis of SARS [20]. Jia et al. [21] have investigated
interactions between SARS-CoV and human airway epithelia and
indicated that the state of cell differentiation and ACE2 expression
levels are important determinants of the susceptibility of human
airway epithelia to infection. To date, the molecular switches
regulating the state of cellular differentiation of an infected cell and
ACE2 expression have not been studied properly. In this work, we
have proposed the role of miRNA in modulating the expression of
ACE2 along with the stage specific cellular differentiation at the
site of infection initiation. Further we have tried to focus on the
role of SARS-CoV which dictates these events for its successful
transmission and replication.
The POU-homeodomain transcription factor Oct-4 (Pou5f1)
plays a central role in self-renewal, pluripotency, and lineage
commitment. Alterations in Oct-4 expression promote differenti-
ation and leads to the specification of ectodermal, endodermal or
mesodermal primitive progenitors [22]. A small number of Oct-4-
expressing cells have been observed at the bronchoalveolar
junction of the neonatal lung [8]. We have investigated miRNA-
mediated modulatory role on Oct-4+ BASCs and have correlated
their contribution to SARS infection.
Our analysis establishes a complex interplay between miR-
NAs, BASCs and certain essential factors related to the disease
which might provide a better understanding of SARS patho-
genesis. The multifarious relationships shared by genes related to
the disease-system pathway, modulatory effects of miRNAs
within the prime target cells of infection in response to indefinite
cues impose the need of an interaction map. This study develops
a complex interaction map between disease-related factors,
miRNAs and BASCs in SARS disease pathway, which will
provide some clues for diagnostic markers to view an overall
interplay leading to disease progression. Further, our investiga-
tion towards investigating the therapeutic potential of miRNA-
mediated RNAi as an effective antiviral agent against SARS
might unravel some of the efficient therapeutic measures against
the deadly disease in future.
Results and Discussion
We have investigated the cellular tropism of SARS-CoV
(Table 1) in the BASCs present in lungs and attempted to
establish the role of BASC-miRNAs towards understanding the
pathogenesis of SARS in lung fibrosis. We describe the role of
BASCs as the target cells of SARS infection and show how a
repertoire of BASC miRNAs act as molecular switches to
contribute to this host-pathogen interaction.
Primary site of SARS infection
Which is the primary site of SARS infection and how do these
corona virus interacts with those cells to enter the host and
eventually invades the host immune system to spread itself - is a
pertinent question which prevails and is a debated issue. In order
to throw light on this very important question, we looked upon at
the SARS
+ cell markers and BASC markers (specific to each of its
developmental stages from multipotent state to fully differentiated
state).
It has been reported that SARS-infected cells are unlikely to be
pneumocytes (both type I or type II) or cytokeratin
+ epithelial
cells and it is quite obvious since SARS-CoV cannot infect or
replicate in a fully differentiated cell [23]. Further, SARS
+ cells
are distinct from cells expressing the macrophage/monocyte
specific marker CD68. But SARS
+ cells are found to express the
functional receptor ACE2 as well as the stem/progenitor cell
marker CD34 and Oct-4 [23]. Chen et al have also shown that
SARS
+ cells are CD45
2. Hence it has been confirmed that the
SARS
+ cells in the infected lung were a subset of putative stem/
progenitor cells expressing CD34, Oct-4 and ACE2. Further, it is
unlikely for SARS
+ cells to produce differentiated cell markers.
T h ep r e s e n c eo fS A R S
+ cells within the multiple cell types at the
bronchiolar lining layers makes it difficult to isolate SARS
+ cells.
Some of the SARS
+ cells remains overlapped with adjacent
cytokeratin
+ cells which might be mistakenly interpreted as
colocalized cells. In suchas i t u a t i o nB A S C( S c a - 1
+ CD34
+
CD45
2 Pecam
2)i nt e r m i n a lb r o n c h i o l e sl o c a t e de x c l u s i v e l ya t
the broncho-alveolar duct junction (BADJ) stands a good
selection to be investigated as the prime target cells of SARS-
CoV infection.
miRNA Regulation in BASCs
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SARS infection initiation
A percentage of the Sca-1
+ CD4
2 Pecam
2 cell populations at
BADJ are CD34
+. This Sca-1
+ CD34
+ CD45
2 Pecam
2
population is enriched for BASCs [12] became evident from the
fact that it contained no ciliated cells. In addition to clonal colony
formation, these cells exhibited extensive self-renewal in culture.
They also had a greater capacity for differentiation compared to
other lung epithelial cells. Sca-1
+ CD34
+ CD45
2 Pecam
2 BASC
cultures further confirmed the multilineage differentiation capacity
of BASCs. Within seven to ten days they show up positive for
differentiated cell markers as they get differentiated into Clara-like
cells (CCA
+ SP-C
2), AT2-like cells (SP-C
+ CCA) and AT1-like
cells (AQ5
+).
Within the Sca-1
+ CD4
2 Pecam
2 cells the other percentage of
cells showed CD34
2 and contained ciliated cells. The Oct-4
+
colony cells which are Sca-1
+ CD34
2 SSEA-1
+ cytokeratin
+ were
shown to be succeptible to SARS-CoV infection by Ling et al. [8].
These might be a subset of Sca-1
+ CD4
2 Pecam
2 CD34
2
population (Figure 1). Later studies have shown that cytokeratin
+
cells do not express the functional receptor ACE2 [23]. Further,
SARS
+ cells do not express cytokeratin and are CD34
+ SSEA-1
2.
Phagocytosis is a common mode of virus entry within surrounding
cells in SARS infection [24]. Hence, presence of SARS antigen
within the subset of Oct-4
+ colony cells which are Sca-1
+ CD34
2
SSEA-1
+ cytokeratin
+ is most likely due to phagocytosis. Thereby,
it is evident that these Oct-4 cells (Sca-1
+ CD34
2 SSEA-1
+
cytokeratin
+) are not the prime target cells for SARS-CoV
infection.
On the contrary, the BASCs (Sca-1
+ CD34
+ CD45
2 Pecam
2)
must be another subset of these Oct-4
+ ACE2
+ epithelial colony
cells (Figure 1) which provides a more favorable environment for
SARS-CoV entry and replication. Absence of ciliated cells and
CD34
+ makes them the most probable targets of SARS-CoV at
the onset of infection.
miRNAs as modulators of BASC differentiation
Since SARS-CoV cannot infect or replicate in a fully
differentiated cell, it is indeed essential for the virus to control
the differentiation stages in an infected BASC cells so that they do
not reach a fully differentiated state until the virus has undergone
successful transmission and replication within this primary site of
infection. Hence, it is important to monitor the expression levels of
the different developmental stage specific markers of SARS
infected BASC and also that of the corresponding regulatory
switches that control their level of expression.
MiRNAs are widespread agents of post-transcriptional gene
silencing and have been strongly linked with stem cells [25,26].
They exhibit a high degree of stage- and tissue-specificity, and
therefore it is important to scan the profiling data for those
miRNAs that operate during the narrow windows of development
of a BASC in order to understand their regulatory impact on the
expression levels of essential marker genes and transcription
factors within the cell. In order to model the regulatory
mechanisms within a SARS
+ cell, we have tried to understand
the underlying regulatory mechanisms within a normal BASC cells
mediated by the molecular switches- the miRNAs.
It has been established that the virus exploits the host-miRNA
milieu to foster their own agenda of evading the host immune
system, thereby establish a consistent infection and continue
replication.
mh–miRNAs targeting host factors
We undertook an intensive transcriptome-wide search for
candidate mh-miRNAs (BASC-miRNAs which are homologous
between mouse-human whole genomes) (Table 2) targeting the
developmental stage specific transcriptional factors and marker
genes of BASCs. Table 3 shows the list of the miRNAs targeting
the potential stage specific factors of BASCs. Further, we have also
elucidated the mh-miRNAs targeting ACE2. The target factors
have further been mapped with the expression levels of their
corresponding miRNAs within BASCs which shows their
integrated correlation contributing towards each developmental
stage of BASCs in a healthy individual (Figure 2). SARS-CoV
definitely interferes with these miRNA mediated regulation to
dictate the cell fate and continue its replication. Hence as a future
advancement of this work, it will be worthy designing benchwork
to detect the correlation of these miRNA-mRNA expressions
within a SARS-CoV infected cell.
Host miRNA targets in viral genome
We have searched for the host miRNA targets within the
virulent genes of SARS-CoV. Table 4 includes the BASC-miRNA
candidates targeting the most important virulent proteins
responsible for viral infection. Interestingly, miRNAs-17*, -574-
Table 1. SARS-CoV strains considered in our study.
Name of the Strains Accession no.
SARS coronavirus Urbani AY278741
SARS coronavirus ZJ01 AY286320
SARS Coronavirus CDC#200301157 AY714217
SARS coronavirus Taiwan TC1 AY338174
SARS coronavirus Taiwan TC3 AY348314
SARS coronavirus ZJ0301 from China DQ182595
SARS coronavirus TOR2 AY274119
SARS coronavirus GD01 AY278489
SARS coronavirus FRA AY310120
SARS coronavirus Shanhgai LY AY322207
SARS coronavirus NS-1 AY508724
SARS coronavirus civet007 AY572034
SARS coronavirus civet010 AY572035
SARS coronavirus civet020 AY572038
SARS coronavirus TJF AY654624
SARS coronavirus B039 AY686864
SARS coronavirus A022 AY686863
SARS coronavirus WH20 AY772062
SARS coronavirus TWH AP006557
SARS coronavirus TWJ AP006558
SARS coronavirus TWK AP006559
SARS coronavirus TWS AP006560
SARS coronavirus TWY AP006561
SARS coronavirus Frankfurt 1 AY291315
SARS coronavirus HSR 1 AY323977
SARS coronavirus Sino3-11 AY485278
SARS coronavirus Sino1-11 AY485277
SARS coronavirus ShanghaiQXC2 AY463060
SARS coronavirus ShanghaiQXC1 AY463059
SARS coronavirus LLJ-2004 AY595412
doi:10.1371/journal.pone.0007837.t001
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E and orf1a. miR-148a has its target in ORF1a, E, S and M. miR-
223 and miR-98 has an exclusive correlation with their targets
within the 39 UTRs of N and S respectively (Figure 2).
Normally presence of such host miRNA targets in SARS-CoV
genome indicates that the corresponding miRNAs are a part of the
host’s innate antiviral defense. On the contrary, the RNA virus co-
opt host-miRNAs to suppress their own replication to evade
immune elimination and establish a strong infection. It has been
found that human infecting single-stranded RNA viruses are
enriched for target sequences of human miRNAs [42]. Or else
rapidly evolving RNA viruses might evolve targets that match host
miRNAs in order to increase their host specificity. It is very likely
that the rapidly evolving virus take advantage of slowly evolving
host miRNAs to increase their survival in the host, analogous to
the manner in which viruses take advantage of other cellular
processes. Co-option of host miRNAs by SARS-CoV to suppress
their own replication will allow it to be in a latent state and escape
the host immune system at the initial time point of transmission
and infection. Once successful transmission within the host system
takes place, antiviral miRNA target sequences in the virus can be
expected to mutate rapidly to maximize mismatches and thus
minimize the impact of ‘antiviral’ miRNAs. Rapid mutation in
SARS-CoV is supported by the fact that SARS-CoV lack proof
reading activity in their polymerases. RNA-dependent polymerase
in SARS-CoV misincorporates 8.26 bases per million [43].
While investigating the seed sequence conservation of the viral-
specific host miRNAs (Figure 3) we found that there is a strong
bias towards G, Y(pYrimidine) and R (PuRine) bases at the 3
rd,4
th
and 5
th position respectively of the seed region. This implies that a
single mutation within the complementary regions of this
conserved 3-mer motif within the viral targets will disrupt the
miRNA seed-target match and will enable the virus to escape the
antiviral effect of host-miRNAs after successful transmission within
the host. Such host-miRNA sequence conservation helps the virus
to mutate the target regions with more precision and at ease so as
to escape the effect of all the 4 miRNAs together.
The miRNA expression profiles of three miRNAs-17*, -574-5p
and -214 targeting S, N, Orf1a, M and E shows that they are
upregulated within uninfected BASCs. Presumably at the onset of
SARS infection the expression of these targets is suppressed which
is likely to control viral replication and consequently help the virus
to evade the host immune system. But the targets for downreg-
ulated miR-148a within ORF1a, M, S and E might escape
repression and maintain replication at a lower rate. Further, the
exclusive miRNAs viz. miR-223 and -98 for N and S protein
respectively are highly downregulated (8.7 fold and 5.6 fold
respectively) in BASCs. N and S proteins are important for viral
transmission in host. This provides a clue towards the fact that the
S protein and N protein (having targets corresponding to these
miRNAs) of SARS-CoV takes advantage of this and escapes
miRNA-mediated repression which is a rescue to the virus for
effective transmission at the initial stage of viral infection.
Key miRNA–mRNA pairs correlating with virus entry,
replication, and host–virus interaction
ACE2-S interaction. It has been shown that proinflamm-
atory and fibrogenic cytokine pathways are activated within the
first 24–48 hr following pulmonary insult resulting from SARS-
CoV infection [44]. High initial levels of these activities are
associated with persistent pulmonary damage and increased risks
of subsequent pulmonary fibrosis and poor outcome in diffuse
Figure 1. Lower respiratory tract focusing on bronchoalveolar duct junction (BADJ) of the lung. Venn diagram represents an enlarged
section of the BADJ showing up the different subsets of the distinct cellular population (Oct-4
+ ACE2
+) in this region of the lung. A subset of this
cellular population is enriched in BASCs identified as Sca-1
+ CD45
2 Pecam
2 CD34
+, the other subset being Sca-1
+ CD45
2 Pecam
2 CD34
2.O n
differentiation Sca-1
+ CD45
2 Pecam
2 CD34
+ cells show positive for CCA and SP-C; Sca-1
+ CD45
2 Pecam
2 CD34
2 cells show positive for CCA, SP-C,
and ciliated cells.
doi:10.1371/journal.pone.0007837.g001
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alveolar stem cells.
miRNAs Mouse Accession No. Human Accession No.
miR-142-3p MIMAT0000155 MIMAT0000434
miR-19a MIMAT0000651 MIMAT0000073
miR-144 MIMAT0000156 MIMAT0000436
miR-374 MIMAT0003727 MIMAT0004955
miR-7a MIMAT0000677 MIMAT0000252
miR-186 MIMAT0000215 MIMAT0000456
miR-15b* MIMAT0004521 MIMAT0004586
miR-340-5p MIMAT0004651 MIMAT0004692
miR-223 MIMAT0000665 MIMAT0000280
miR-451 MIMAT0001632 MIMAT0001631
miR-106a MIMAT0000385 MIMAT0000103
miR-140 MIMAT0000151 MIMAT0000431
miR-421 MIMAT0004869 MIMAT0003339
miR-142-5p MIMAT0000154 MIMAT0000433
miR-20b MIMAT0003187 MIMAT0001413
miR-98 MIMAT0000545 MIMAT0000096
miR-92a MIMAT0000539 MIMAT0000092
miR-15b MIMAT0000124 MIMAT0000417
miR-146b MIMAT0003475 MIMAT0002809
miR-20a MIMAT0000529 MIMAT0000075
miR-301a MIMAT0000379 MIMAT0000688
miR-148b MIMAT0000580 MIMAT0000759
miR-15a MIMAT0000526 MIMAT0000068
miR-218 MIMAT0000663 MIMAT0000275
miR-17 MIMAT0000649 MIMAT0000070
miR-106b MIMAT0000386 MIMAT0000680
miR-25 MIMAT0000652 MIMAT0000081
miR-486 MIMAT0003130 MIMAT0002177
miR-193 MIMAT0000223 MIMAT0000459
miR-151-5p MIMAT0004536 MIMAT0004697
miR-93 MIMAT0000540 MIMAT0000093
miR-101b MIMAT0000616 MIMAT0000099
miR-127 MIMAT0000139 MIMAT0000446
miR-483 MIMAT0004782 MIMAT0004761
miR-574-5p MIMAT0004893 MIMAT0004795
miR-21 MIMAT0000530 MIMAT0000076
miR-200b MIMAT0000233 MIMAT0000318
miR-342-3p MIMAT0000590 MIMAT0000753
miR-151-3p MIMAT0000161 MIMAT0000757
miR-429 MIMAT0001537 MIMAT0001536
miR-335-5p MIMAT0000766 MIMAT0000765
miR-16 MIMAT0000527 MIMAT0000069
miR-181d MIMAT0004324 MIMAT0002821
miR-99b MIMAT0000132 MIMAT0000689
miR-146a MIMAT0000158 MIMAT0000449
miR-331-3p MIMAT0000571 MIMAT0000760
miR-574-3p MIMAT0004894 MIMAT0003239
miR-10a MIMAT0000648 MIMAT0000253
miR-200a MIMAT0000519 MIMAT0000682
miRNAs Mouse Accession No. Human Accession No.
miR-423-5p MIMAT0004825 MIMAT0004748
miR-17* MIMAT0000650 MIMAT0000071
miR-671-5p MIMAT0003731 MIMAT0003880
miR-126-3p MIMAT0000138 MIMAT0000445
miR-125a-5p MIMAT0000135 MIMAT0000443
miR-92b MIMAT0004899 MIMAT0003218
let-7d* MIMAT0000384 MIMAT0004484
miR-27a MIMAT0000537 MIMAT0000084
miR-214 MIMAT0000661 MIMAT0000271
miR-150 MIMAT0000160 MIMAT0000451
miR-652 MIMAT0003711 MIMAT0003322
miR-210 MIMAT0000658 MIMAT0000267
miR-18a MIMAT0000528 MIMAT0000072
miR-361 MIMAT0000704 MIMAT0000703
miR-152 MIMAT0000162 MIMAT0000438
miR-24 MIMAT0000219 MIMAT0000080
miR-148a MIMAT0000516 MIMAT0000243
let-7g MIMAT0000121 MIMAT0000414
miR-19b MIMAT0000513 MIMAT0000074
miR-130b MIMAT0000387 MIMAT0000691
miR-128 MIMAT0000140 MIMAT0000424
miR-181b MIMAT0000673 MIMAT0000257
miR-29b MIMAT0000127 MIMAT0000100
miR-455 MIMAT0003742 MIMAT0004784
miR-221 MIMAT0000669 MIMAT0000278
miR-30c MIMAT0000514 MIMAT0000244
miR-27b MIMAT0000126 MIMAT0000419
miR-30a MIMAT0000128 MIMAT0000087
miR-320 MIMAT0000666 MIMAT0000510
miR-23b MIMAT0000125 MIMAT0000418
let-7d MIMAT0000383 MIMAT0000065
miR-23a MIMAT0000532 MIMAT0000078
miR-125b-5p MIMAT0000136 MIMAT0000423
miR-30d MIMAT0000515 MIMAT0000245
let-7a MIMAT0000521 MIMAT0000062
miR-199a-5p MIMAT0000229 MIMAT0000231
miR-26a MIMAT0000533 MIMAT0000082
miR-191 MIMAT0000221 MIMAT0000440
miR-30e MIMAT0000248 MIMAT0000692
miR-30b MIMAT0000130 MIMAT0000420
miR-26b MIMAT0000534 MIMAT0000083
miR-181a MIMAT0000210 MIMAT0000256
miR-143 MIMAT0000247 MIMAT0000435
miR-195 MIMAT0000225 MIMAT0000461
miR-145 MIMAT0000157 MIMAT0000437
let-7c MIMAT0000523 MIMAT0000064
mh-miRNAs- mouse miRNAs having complete homology with human miRNAs.
doi:10.1371/journal.pone.0007837.t002
Table 2. Cont.
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protein and enzymatic activity is severely decreased in pulmonary
fibrosis resulting from SARS-CoV infection [17,18]. Studies have
also been performed which support that differential regulation of
host cell mRNA transcription and protein synthesis occurs in a
SARS-CoV infected cells [45].
SARS-CoV S protein is a multifunctional protein which plays
pivotal roles in the biology and pathogenesis of SARS-CoV. It has
been shown that S protein mediates viral infection by binding to
cellular receptor ACE2 and thus induces membrane fusion.
SARS-CoV infections and the Spike protein of the SARS-CoV
reduce ACE2 expression [46]. Further a recent work of Imai et al.
showed that on injecting SARS-CoV Spike into mice worsens
acute lung failure in vivo, which can be attenuated by blocking the
renin–angiotensin pathway. This suggests that the S-protein
mediated activation of the pulmonary RAS influences the
pathogenesis of ALI/ARDS and SARS [47]. But the molecular
mechanism by which S protein down regulates ACE2 in lung cells
following SARS injury is not well addressed till to date.
In our work we observed that the miRNAs- miR-186,-93 and
-200b targeting ACE2 are found to be highly down regulated in
normal BASCs thereby showing that they do not interfere with the
expression level of ACE2 and thus prevents lung fibrogenesis by
limiting the local accumulation of the profibrotic peptide ANG II
in an uninfected state. Considering the expression of S-protein, we
find that its target corresponding to highly downregulated miR-98
probably escapes miRNA-mediated host RNAi defense at the
onset of infection and interferes with ACE2 expression. Figure 4
shows how the virus takes advantage of the microRNA-mediated
complex interplay between the host and viral factors within
BASCs. The question still remains regarding the molecular
mechanism by which this S-protein represses the expression of
ACE2.
S-proteins have been shown to act as transcription factor
activating the promoters of GRP94/78 genes inducing ER stress
in a SARS-CoV infected cell [48]. The role of S protein as a
transcription factor has obliged us to think that they might play a
role to activate the miRNA promoters of miR-186,-93 and -200b
targeting ACE2 to enhance their expression resulting in a reduced
expression of ACE2 in an infected host. Whether this decrease in
ACE2 expression is a result of miRNA mediated gene silencing
controlled by S-protein will be an interesting and compelling
question for further study.
Oct-4-N interaction. Oct-4 plays a crucial role towards
regulating the chromatin structure in a state consistent with self-
renewal and later facilitating the expression of genes that keeps the
cell poised to respond to cues that lead to differentiation. Hence
this is one of the essential factors which control the state of
differentiation in BASCs. Furthermore, it has a significant role in
apoptosis. miR-146b-5p is seen to target Oct-4 in normal BASCs.
The downregulated expression of this miRNA explains for the
uninterrupted expression of Oct-4 resulting its normal function in
an uninfected cell. We have harnessed the high possibility of a
complicated crosstalk between the ability of N-protein to control
the expression of Oct-4 in an infected cell.
N protein is known to be the most abundantly expressed protein
of SARS-CoV. The most unique and significant property of it is
revealed in its ability to act as a sequence specific DNA binding
factor. It has been reported to bind NFkB response element of
COX2 promoter and enhance COX2 gene expression [49] which
effectively is beneficial for its existence within the host. This reveals
the power of the N-protein to manipulate the entire gene
expression programme of the infected cell. The common miRNAs,
miR-214,-574-5p and -17* having targets in N protein are
upregulated in BASCs. But miR-223, the unique miRNA targeting
N-protein is highly downregulated. This signifies that the N-
protein targets corresponding to miR-223 is going to escape
miRNA-mediated downregulation at the onset of infection (See
Figure 4). Further it seems that N-protein plays a role in interfering
with the expression modulation of Oct-4 by binding to the
promoter of miR-146-5p and controls the different stages of BASC
differentiation as well as prevents apoptosis of SARS infected cells.
Table 3. Predicted miRNA–mRNA pairs within the host
system.
Target Genes mh-miRNAs Functions
Class A
SCA1 (ATXN1) miR-101
miR-19b
miR-200a
miR-106a
miR-93
miR-150
Stem Cell Antigen-1 is identified as a
potential marker for BASCs located at the
BADJ [12,27].
OCT4 (POU5F1) miR-146b-5p Octamer-binding transcription factor 4+ (Oct-
4) is a stem cell marker protein. It acts as a
master switch in differentiation by regulating
cells that have pluripotent potential.
Recently, it has been found to be expressed
in pulmonary cells which are a target for
SARS infection [8,23].
CD34 let-7g
let-7d
let-7c
These are membrane-bound stem cell
markers for BASCs. This is also expressed in
SARS-infected lung cells [23,28].
Class B
SP-C (SFTPC) miR-331-3p Marker protein of alveolar type-2(AT2-like)
cells which is a subset of the differentiated
BASCpopulation.Henceisquiescentinnormal
lung but proliferate in response to bronchiolar
and alveolar epithelial injury [29,30].
CCSP-2 miR-181a
miR-497
This is the Clara cell marker protein. These are
also quiescent in normal lung and proliferate
in response to bronchiolar and alveolar
epithelial injury [30].
Aquaporin5 miR-331-3p
miR-497
Marker protein of AT1-like cells which is
another subset of the differentiated BASC
population. Aquaporin5 plays a critical role in
the maintenance of normal lung water
homeostasis [30,31].
Class C
ACE2 miR-186
miR-93
miR-200b
Angiotensin-converting enzyme 2 (ACE2), the
primary receptor of SARS-CoV on the host cell.
It is a negative regulator of the rennin-
angiotensin system (RAS) in the setting of
acutelunginjuryandinresponsetopulmonary
infection with the SARS-CoV [17,32].
CCR1 miR-223 Inflammatory chemokine receptor for CCL3
and CCL5 & responsible for lung fibrosis
[33,34].
We have predicted the differentially expressed mh–miRNAs which operate
within the narrow windows of development of BASCs by targeting a set of host
encoded mRNAs.
Class A specifies the host mRNAs corresponding to BASC marker proteins
which designates its undifferentiated state as well as the state of proliferation
and/initiation of differentiation.
Class B specifies the host mRNAs corresponding to BASC marker proteins as it
reaches a fully differentiated state.
Class C specifies the host mRNAs corresponding to the receptor proteins
which participates in SARS-CoV pathogenesis.
These miRNA–mRNA pairs specific to BASC are important to understand host-
virus interaction network.
doi:10.1371/journal.pone.0007837.t003
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chemokines in SARS-CoV–infected cells might be an
advantage for the virus to replicate
All respiratory virus disease results from two concurrent
pathological components: ongoing virus replication and the
resulting inflammatory response. Even if antivirals clearly inhibit
virus replication, the biochemical and cellular inflammatory
responses to the initial infection related events continue despite
diminished virus titer [50]. While acute inflammatory responses are
generally beneficial in nature and have been shown to limit virus
replication in situ, prolonged, uncontrolled inflammation has been
recognized as a significant component contributing to the
pathological sequelae to the morbidity and mortality of severe
acute respiratory syndrome coronavirus infection [44]. A histo-
pathologic analysis of SARS-CoV infected lung in miceshowed that
there has been an induction of significant changes in the expression
levels of the chemokine receptor CCR1 which acts as receptors for
CCL3 and CCL5. The expression levels of these inflammatory
chemokines were increased by viral infection of the lung [33]. It has
been shown that CCR1 play an essential role in the pathogenesis of
pulmonary fibrosis in lung-injury models [34]. Further, previous
work suggests that antagonism of signaling via the chemokine
receptor CCR1 is a potent strategy that attenuates leukocyte
recruitment in response to severe respiratory virus infection [50].
Although there has been a subsequent increase in inflammatory
cytokines related to innate immune response in response to viral
infection, there has been a lack of immunoregulatory cytokines (T
or B lymphocytes) in the lung during infection which confirms the
fact that the expression of viral replication proteins remains at a
quiescent state so as to avoid viral clearance by the activation of
immunoregulatory cytokines by adaptive immune responses at the
onset of the infection. On the contrary, activation of inflammatory
chemokines might be acting as a beneficial phenomenon for the
replication of various viruses [51,52].
Emerging studies suggest that miRNAs provide an added layer
in orchestrating immune responses [53]. miRNAs function in
shaping immunity by regulating the repertoire of genes expressed
in immune cells and the magnitude and duration of responses to
particular pathogens [54]. Hence we investigated the underlying
miRNA induced molecular mechanisms responsible for these
changes in the lung and we found that miR-223 has its target in
the 39-UTR of CCR1. Previously, miR-223 was experimentally
identified in chorioamnionitis-related inflammation and its
predicted target genes include several genes involved in inflam-
mation and immune responses. Further, miR-223 is known to
promote granulocyte differentiation and is a part of a regulatory
loop that involves C/EBP and NFI-A [55].
Interestingly miR-223 has its target in N protein of SARS-CoV
too and it is one of the miRNAs which probably helps the virus to
escape the RNAi mediated silencing at the onset of infection. Or in
another way we may say that the virus encodes the target of miR-
223 to escape the RNAi mediated repression and at the same time
Figure 2. Fold change of the differentially expressed host miRNAs in BASC targeting host and virulent viral factors [61].
doi:10.1371/journal.pone.0007837.g002
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chemokine responses to accelerate lung fibrosis. But the controlled
expression of target CCR1 in an uninfected cell inspite of the
significantly low expression of its corresponding miR-223 in
BASCs suggest that there must be a cascaded fine tuned
interaction masterminded by the virus which is going on within
the infected cell. It is known that N protein activates NF-KB in
Vero E6 cells [38]. CCR1 is one of the target genes of NF-KB
which is activated at a later stage [56]. Hence, we propose that
within BASCs, reduced expression of miR-223 helps N protein to
enter the host cell. On successful entry, N protein might be using
miR-223 once again to activate CCR1 via NF-KB at its replicative
stage to enhance lung fibrosis and at the same time gets
empowered to manipulate the entire gene expression of the host
cell by controlling the expression of Oct-4. The exact mechanism
of such miRNA-mediated events needs further investigation.
Further, checking the expression levels of N-protein, CCR1 as well
as miR-223 in an infected BASC will provide a more compact
conclusion.
Conclusion
Based on these findings, we propose that BASCs (Sca-1
+ CD34
+
CD45
2 Pecam
-) are a subset of Oct-4
+ ACE2
+ cells and are the
chief targets of SARS-CoV infection. SARS-CoV enters the host;
infects the BASCs of the lungs and controls its developmental
stages via the molecular switches-miRNAs. Co-option of host
miRNAs by viruses reveal their intelligent plan to control their
replication in order to evade immune elimination until they
undergoes successful transmission and establish a strong infection.
Thereafter, they undergo rapid mutation to maximize the target-
miRNA mismatches and enhance their replication before the cell
reaches at a fully differentiated state. On successful replication, the
virus infects resident, infiltrating, and circulating immune cells.
The circulating immune cells carry the virus to other organs and
causes damages to the immune cells of spleen, peripheral and
central lymph nodes and other lymphoid tissues. The immune
defense being weakened significantly, leads to rapid deterioration
of the pneumonia. It is worth to test these cells for the expression
of Oct-4 and ACE2 for further confirmatory conclusion.
The proposed host miRNA-dependent mechanism probably
acts in concert with the host and viral factors for establishing a
strong infection. Our proposal shifts away from the simplistic
notion that host miRNAs with specific sequence complementarity
to viruses are indicative of a bonafide innate antiviral immune
mechanism to an established viral pathogen.
Although the immediate threat of SARS is over, we intend to
continue with its therapeutic measures partly to guard for its
possible return. Moreover, this will help us to transform our
knowledge from SARS to other emerging viral diseases specially
causing lung injuries which most certainly will be a deadly threat
in future. Lot of attempts have been made and is still going on to
design effective antiviral agents against this deadly disease [57–60].
While some of these approaches showed partial efficiency to
combat SARS infection, the others need further clinical investi-
gations to be used as a proper therapeutic reagent.
This era has witnessed an increase in the development of
exogenous siRNA therapeutics against viruses. The potential
therapeutic effect of modulating host-miRNA levels is also worth
considering. This emerging picture of miRNA regulation in
SARS-CoV infected individual will make the host-virus interaction
far richer and more complex than the crisp linear pathways of the
previous decade, with miRNAs participating in executive decisions
at the interesting and vulnerable nodes in regulatory networks. By
boosting the level of the host virus-specific miRNAs, it might be
possible to turn what was a desirable outcome for the virus into a
desirable outcome for the patient. Under the current hypothesis,
we would predict that decreasing the level of host virus-specific
miRNAs would result in promotion of viral replication, leading to
immunological recognition and clearance of the virus by the host
immune system. Further, increasing the level of miRNAs exclusive
for the N and S protein might also block viral entry. However,
manipulating the level of host miRNAs could have unintended
consequences because the physiological functions of the miRNAs
might be altered or viral pathology might be enhanced. Further
silencing of miRNAs with antagomirs specifically within the
infected cell could become another therapeutic strategy where
miRNAs participate in disease aetiology. Nevertheless, these
potential interventions merit further evaluation.
Materials and Methods
To identify the miRNAs involved in the cellular tropism of
SARS-CoV in lungs, we undertook an intensive search for
potential miRNA candidates in the BASCGAP (Broncho-alveolar
Figure 3. Sequence alignment between the common viral
specific host miRNA mature sequences from 59 to 39 end. The
seed region (position 2 to 7) and the conserved positions (3
rd,4
th, and
5
th) within the seed region are highlighted within boxes.
doi:10.1371/journal.pone.0007837.g003
Table 4. Host miRNAs targeting virulent protein coding
mRNAs of SARS-CoV.
Target genes mh-miRNAs Functions of target genes
Spike (S) miR-214
miR-574-5p
miR-17*
miR-148a
miR-98
Responsible for viral attachment and
entry into host cells by interacting with
ACE2 [5,35]
Envelop (E) miR-574-5p
miR-214
miR-17*
miR-148a
E is responsible for virion envelope
morphogenesis and acts as a viroporin,
inducing the formation of hydrophilic
pores in cellular membranes [36]
Membrane (M) miR-574-5p
miR-214
miR-17*
miR-148a
Induction of apoptosis [37]
Nucleocapsid (N) miR-574-5p
miR-214
miR-17*
miR-223
Promotes tissue fibrosis [19]
N protein inhibit cell cycle progression
[38,39]
ORF1a miR-574-5p
miR-214
miR-17*
miR-148a
Encodes viral replicase proteins [40,41]
doi:10.1371/journal.pone.0007837.t004
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sequences were derived from the Sanger Institute miRBase release
12.0 (http://microrna.sanger.ac.uk/sequences). The global
miRNA expression profile of our BASCGAP source sequences
were derived from mouse BASCs [61].
miRNA—mouse-human (mh–miRNA)
Our search strategy was motivated by the need to apply pure-
homology based selection of miRNAs so that the results represent
a closer approach to mimic the molecular mechanisms that underlie
disease pathway behaviors and response in a human host. Further
the overall miRNAexpression profile ofmouseand human lungsare
similar [62]. From the BASCGAP sequence data of 116 miRNAs,
we screened out the BASC-miRNAs lying at the intersection of
mouse-human whole genomes. This filter is based on a homology
search (SSEARCH), performed with miRBase (release 12.0) and is
applied on the mature candidates from the BASCGAP sequence
data. E-value cutoff considered for SSEARCH was ,10.0. Mature
miRNA sequence homology was one of the stringent parameters
considered in our search. Table 2 represents the screened output set
of 95 mature candidates termed as mh-miRNAs.
mRNA targets
We have considered the developmental stage specific marker
proteins of BASCs, which includes the transcription factor Pou5f1;
ACE2-the most important receptor of SARS-CoV (Table 3). In
addition to these, we have chosen the virulent protein coding
genes, viz. Nucleocapsid (N), Spike(S), Envelope (E), Membrane
(M) and Orf1a from 30 strains of SARS-CoV (Table 1 and
Table 4) for our investigation. Annotated UTR sequences of the
target genes were retrieved from UTRdb [63].
Target prediction
We adopted RNAhybrid [64], that predicts the most favorable
hybridization sites between miRNA and UTR regions and
generates energy minimized duplex structures using the Dynamic
Programming technique. The resultant miRNA-mRNA duplexes
are consistent with the following structural and energy constraints
at the first step of screening the targets: (i) Binding energy cutoff
,=220 kcal/mol [64]; (ii) complementarity of minimum seven
bases to the 59 end of the miRNA; (iii) minimization of GU base
pair within the miRNA-target duplex, a maximum of only one GU
base pair between 2 and 7 position of the miRNA is allowed; (iv)
minimization of loop size throughout the duplex.
Although, currently available target prediction methods are
diverse, both in approach and performance and all have room for
further improvement, perfect seed pairing centered on nucleotides
2–7 is considered as the most important criteria for prediction
reliability. Furthermore, in order to screen out the most favorable
target in the case of miRNAs having multiple targets we
Figure 4. Modelled miRNA–mediated host–virus interaction within BASC in SARS-CoV pathogenesis. Host miRNAs are central to viral
pathogenesis. This figure illustrates how the host miRNA and SARS-CoV interactions can explain the features of SARS-CoV pathogenesis such as (A)
entry of the virus in an undifferentiated BASC, (B) causing acute infection during the proliferative stage and onset of BASC differentiation, and (C)
complete clearance of virus in a fully differentiated BASC.
doi:10.1371/journal.pone.0007837.g004
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efficacy follows- 8 mer.7 mer-m8.7 mer-A1.6 mer) following
the work of Grimson et al. and Friedman et al. [65,66]. 39
compensatory pairing of miRNA to its target have been
considered to compensate for imperfect/weak seed matches [67].
We have further checked the effect of cooperativity as well as the
UTR binding location.
miRNA–mRNA enrichment analysis
For bantam miRNAs, good minimum free energies (MFEs) can
occur frequently by chance. The longer a putative target sequence,
the better such random energies will be. Hence, statistical
significance of predicted targets is assessed with an extreme value
statistics of length normalized minimum free energies and a
Poisson approximation of multiple binding sites.
Microarray data analysis in BASCs
miRNA expression profile of 2610
6 mouse BASCs (CD45
2
CD31
2CD34
+ Sca-1
+) and 4610
6 control cells(CD45
2CD31
2
CD34
2Sca-1
2) are determined using miRNA microarray. The
data considered for our analysis is obtained by first subtracting the
background and then normalizing the signals using a LOWESS
filter (locally weighted regression). Background is determined using
a regression-based background mapping method [68]. The miRNA
dataset was filtered according to the standard procedure to exclude
spots with minimum intensity and size. Further for the dual-sample
experiments, the ratio of the two sets of detected signals (log2
transformed, balanced) are calculated. Thereafter, t-values are
calculatedfor each miRNA between the test and the control groups,
and P-values are computed from the theoretical t-distribution.
miRNAs with P-values below a critical P-value (typically 0.01) are
Figure 5. miRNA–mRNA prediction pipelines. This flow chart summarizes the steps followed and yields from BASCGAP consortium sequences
to predict the miRNA-mRNA pairs involved in SARS pathogenesis.
doi:10.1371/journal.pone.0007837.g005
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miRNA expressionprofiledataset(ofmouseBASCs)inBASCGAP.
The flowchart of methodology is provided in Figure 5.
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